Navigation Links
MSU researcher links potentially deadly infection, frequent cow exposure
Date:2/18/2010

EAST LANSING, Mich. A common bacteria found in many healthy adult females that can cause life-threatening infections when passed to newborns could be introduced to some women through frequent contact with cows, according to a research team led by a Michigan State University pediatrician.

The recently published findings that Group B streptococcus could be a zoonotic disease transmitted between different species may have significant public health implications, said Dele Davies, chairperson of MSU's Department of Pediatrics and Human Development.

GBS, first recognized as a bacterium that leads to infections in the breasts of cows, is now found in up to 36 percent of pregnant women in their digestive or genital tracts. When passed to newborns during pregnancy, the infection can be severe leading to death though not all infants become sick.

While GBS affects only 1 in every 2,000 babies, and there are prenatal tests to identify it, Davies said understanding how women are infected could greatly reduce transmission rates.

Efforts have been made to understand the risk factors that lead to transmission from mothers to babies, but it hasn't been established how mothers originally acquire it, Davies said.

As part of the study, Davies, fellow MSU professor Shannon Manning and a team of MSU researchers conducted a cross-sectional cohort study of 68 families and their livestock, collecting and comparing stool specimens. Increased frequency of cattle exposure was significantly associated with human infection, and one couple shared the same GBS strains as their cows, suggesting zoonotic transmission.

"Our study suggests that for at least some women, there is an association between increased exposure to cattle and colonization of the bacteria," he said. "Though GBS human infection has long been suspected as originating from cows, several investigators have suggested that ongoing interspecies transmission is unlikely.<
'/>"/>

Contact: Jason Cody
codyja@msu.edu
517-432-0924
Michigan State University
Source:Eurekalert

0

GOOD

Page: 1 2

Related medicine news :

1. Researchers discover second protective role for tumor-suppressor
2. Researchers chart genomic map spanning over 2 dozen cancers
3. Researchers find biomarkers in saliva for detection of early-stage pancreatic cancer
4. Clemson researchers develop hands-free texting application
5. GUMC researchers say flower power may reduce resistance to breast cancer drug tamoxifen
6. Urine protein test might help diagnose kidney damage from lupus, UT Southwestern researchers find
7. UT researcher receives $2.4 million to research obesity, high-risk pregnancy
8. MSU researcher linking breast cancer patients with alternative therapies
9. Researchers create drug to keep tumor growth switched off
10. Tiny fruit fly could offer big clues in fight against obesity, researcher says
11. Researchers Who Discovered First Genes for Stuttering will Present Findings to the National Stuttering Association
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... (PRWEB) June 18, 2013 The ... battery powered, stand-alone device which can be used to ... stainless steel enclosure of the Temp1000IS comes with the ... with the IFC400 (sold separately) docking station ... for full communications. No more removal of end-caps to ...
(Date:6/18/2013)... 2013 Biomet hip lawsuit ... forward in a multidistrict litigation in U.S. District Court, ... According to court records, the litigation’s most recent status ... the Court also convened a motions hearing and a ... the Biomet hip replacement litigation. The proceeding’s next ...
(Date:6/18/2013)... Hospitals Case Medical Center clinical researchers have launched ... which will evaluate the ability of a patient,s ... end stage peripheral arterial disease (PAD). , ... Surgery at University Hospitals Case Medical Center,s Harrington ... at Case Western Reserve University School of Medicine, ...
(Date:6/18/2013)... June 18, 2013 The Elizabeth Glaser ... State and the U.S. President’s Emergency Plan for AIDS ... celebrate significant new milestones in the global effort to ... Kerry announced that as of June 2013, one million ... support. Since PEPFAR’s inception in 2003, EGPAF has ...
(Date:6/18/2013)... UT (PRWEB) June 18, 2013 Today, ... Health Reimbursement Accounts . Zane Benefits, which provides ... benefits, is the leader in defined contribution ... to Zane Benefits’ website, employees of a company who ... may have questions about how Health Reimbursement Accounts work. ...
Breaking Medicine News(10 mins):Health News:MadgeTech, Inc. Introduces the New Temp1000IS Intrinsically Safe High Temperature Data Logger 2Health News:Biomet Hip Lawsuit News: Bernstein Liebhard LLP Reports on Latest Status Conference in Federal Biomet Hip Replacement Litigation 2Health News:Biomet Hip Lawsuit News: Bernstein Liebhard LLP Reports on Latest Status Conference in Federal Biomet Hip Replacement Litigation 3Health News:UH Case Medical Center launches novel clinical trial using stem cells to prevent amputation 2Health News:One Million Babies Born HIV-free Signals Major Milestone in Global Effort to Eliminate Pediatric AIDS 2Health News:One Million Babies Born HIV-free Signals Major Milestone in Global Effort to Eliminate Pediatric AIDS 3Health News:Zane Benefits Publishes New Information on Health Reimbursement Accounts 2
... ... one-stop, flat-fee healthcare information technology and support, announced it is bringing ... the hiring of new Chief Healthcare Officer Joel Taylor. Taylor joins ... to practices and medical groups of all scopes and sizes, with ...
... Tuesday, October 13, in response to national calls for an ... announce their "patient-centered" plan for health care reform. The ... policy specialist Art Laffer, will be described in detail, together ... to the press (dial-in information is below). , ...
... ... for Cell Sense in vivo imaging agent , ... Pittsburgh, PA (Vocus) October 12, 2009 -- Celsense, Inc. announced today ... imaging reagent, Cell Sense CS-1000 (Cell Sense). , ,Celsense filed a Drug Master File (a “DMF”) ...
... ... help to otherwise untreatable symptoms of Multiple Sclerosis. , ... Camillo, CA (PRWEB) October 12, 2009 -- , , , ,The ... country a sometimes first in years relief from the relentless progressive symptoms of the disease. ...
... is forming the world,s first national centre for research into ... Arthritis Research Campaign and The University of Nottingham, it will ... cause of chronic pain which affects more than ten ... awarded funding of 2.5m over five years and the University ...
... Oct. 11 Canary Foundation, a nonprofit organization that ... its founder and chairman, Don Listwin, has been elected ... (BSA). Members are appointed to 5-year terms by the ... advice on science program policy, programs and initiatives to ...
Cached Medicine News:Health News:ITelagen Taps Joel Taylor as Chief Healthcare Officer New Executive to Spearhead EMR Implementations 2Health News:ITelagen Taps Joel Taylor as Chief Healthcare Officer New Executive to Spearhead EMR Implementations 3Health News:The Obamacare Alternative: 33 State Think Tanks Announce Patient-Centered Health Care Reforms 2Health News:Celsense, Inc Files FDA & EMEA Regulatory Submissions 2Health News:Celsense, Inc Files FDA & EMEA Regulatory Submissions 3Health News:People with Multiple Sclerosis are Proactively Improving their Walking, Energy Level, Confidence and Quality of Life 2Health News:People with Multiple Sclerosis are Proactively Improving their Walking, Energy Level, Confidence and Quality of Life 3Health News:National pain research center will bring hope to millions 2Health News:National pain research center will bring hope to millions 3Health News:National pain research center will bring hope to millions 4Health News:Canary Foundation's Don Listwin Appointed to National Cancer Institute's Board of Scientific Advisors 2
(Date:6/18/2013)... June 18, 2013 Valeant Pharmaceuticals International, Inc. ... "Company") announced today that VPII Escrow Corp., a newly ... launched its offer of approximately $3.2 billion aggregate principal ... will be due in 2021 and in 2023, with ... intends to use the net proceeds from the offering, ...
(Date:6/18/2013)... 18, 2013  Intercept Pharmaceuticals, Inc.  (NASDAQ: ... the development and commercialization of novel bile acid therapeutics ... of an underwritten public offering of 1,730,000 shares of ... $33.01 per share.  In addition, Intercept has granted the ... additional 259,500 shares of common stock. All ...
(Date:6/18/2013)... 2013 Valeant Pharmaceuticals International, Inc. (NYSE: ... previously announced public offering of common shares (the "Offering"). ... common shares at a price of $85.00 per share, ... Company will file a final prospectus supplement to its ... make a similar filing with the securities regulatory authorities ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces Launch Of Private Offering Of Senior Notes 2Valeant Pharmaceuticals Announces Launch Of Private Offering Of Senior Notes 3Intercept Pharmaceuticals Announces Pricing of Public Offering of Common Stock 2Valeant Pharmaceuticals Prices Public Offering Of Common Shares 2Valeant Pharmaceuticals Prices Public Offering Of Common Shares 3Valeant Pharmaceuticals Prices Public Offering Of Common Shares 4
... --,Allos Therapeutics, Inc. today announced that the ... opinion of the Committee for,Orphan Medicinal Products ... orphan drug designation to the Company's novel,antifolate ... with,peripheral T-cell lymphoma (PTCL). In July 2006, ...
... 16, 2007 /PRNewswire/ -- Sirion Therapeutics,Inc., an ... received orphan drug designation from the Food,and ... for the treatment of acute herpetic keratitis. ... in Europe under,the brand name of Virgan(R). ...
Cached Medicine Technology:Allos Therapeutics' PDX Granted Orphan Medicinal Product,Designation by the European Commission 2Allos Therapeutics' PDX Granted Orphan Medicinal Product,Designation by the European Commission 3Allos Therapeutics' PDX Granted Orphan Medicinal Product,Designation by the European Commission 4Sirion Therapeutics Receives Orphan Drug Designation for Ophthalmic,Drug to Treat Viral Eye Infection 2
... High performance fiberoptic imaging from ... ,Olympus has improved its fiberscope range, ... specifications and enhanced image performance. Olympus ... instruments for diagnosis and therapy in ...
... been designed with a large 2.8mm instrument ... This permits the selection of a wide ... procedures. In addition, this model features excellent ... and a bright, high-resolution image. It also ...
Indications For Usage: , Thoracic surgery. , Broncho-spirometry. , Thoracoscopies. , Differential or selective lung ventilation. ...
... Silbroncho is a double lumen tube made of ... tip., ,Due to the characteristics of silicone ... the patient at insertion. Furthermore, the tube will ... suitable for long term surgery., ,Silbronco is ...
Medicine Products: